CoreWeave gets its first downgrade since IPO

Barclays downgraded CoreWeave (CRWV) to equal weight from overweight, citing valuation concerns despite raising the price target to $100, implying only 3% upside from current levels after a 157% surge since its March IPO. Analyst Raimo Lenschow remains optimistic about CoreWeave's long-term potential in GenAI, but believes the current 41x EV/EBIT CY26 multiple, assuming $31.4B in gross debt in CY26, limits near-term upside despite strong Q1 revenue growth of 420% y/y.

Analysis

Barclays has recalibrated its outlook on CoreWeave (CRWV), downgrading the stock to equal weight from overweight, primarily citing valuation concerns after a meteoric 156.9% rise since its initial public offering on March 28. Although Barclays raised its price target to $100 per share from $70, this revised target suggests a modest 3% upside from current trading levels. The stock, which priced its IPO at $40, experienced a particularly sharp ascent of 148% in May alone. Analyst Raimo Lenschow noted that CoreWeave trades at a demanding 41x EV/EBIT CY26 multiple, assuming approximately $31.4 billion in gross debt by CY26, which he views as a significant premium compared to peers, thereby limiting substantial near-term appreciation despite strong fundamental growth. While Barclays remains optimistic about CoreWeave's long-term prospects and its exposure to the Generative AI theme, particularly given its 420% year-over-year revenue growth in Q1 and its strategic position as an AI cloud computing company backed by Nvidia, the current valuation and a perceived lack of immediate catalysts underpin the downgrade. This move by Barclays is notable as it marks the first downgrade from Wall Street firms that had initially issued bullish ratings, including JPMorgan and Bank of America, following the IPO blackout period.

Key Decisions for Investors

• Investors should carefully consider CoreWeave's current rich valuation, trading at a 41x EV/EBIT CY26 multiple, and the limited near-term upside suggested by Barclays' $100 price target, despite the company's strong Q1 revenue growth and long-term GenAI potential.
• Potential investors might await a more attractive entry point or the emergence of new, significant catalysts that could justify further multiple expansion from current elevated levels.
• Existing shareholders who have benefited from the 157% post-IPO rally may consider re-evaluating their positions, balancing the substantial gains against the increased valuation risk highlighted by this first analyst downgrade, whilst still acknowledging the company's significant role in AI infrastructure.